Intraday Info: Juno Therapeutics Inc (NASDAQ:JUNO) locked on 20/12/2016 at $19.11. It has average volume $2.68 million whilst it total volume $2.15M. The company has EPS -2.81 and according to analysts next quarter EPS and next year estimate EPS will -0.63 and -2.84 respectively. And it total income 278.00 million.
Ownership Summary: Juno Therapeutics Inc has total institutional ownership 62.34% while its total outstanding shares 106 millions that’s value of holdings $1,226 million.
Active Positions: In the latest year, JUNO 109 holders have raised its positions while it contains total 6,264,233 shares. And the strength of reduced positions holders and held positions holders are 72 and 24 respectively.
New and Sold Out Positions: In JUNO force of new positions holders 34 and it has total shares 2,452,867. And force of sold out positions holders 31 and it has 1,456,222 shares.
Comparison with Other Company: The Market Value of JUNO is $2M below from Seattle Genetics, Inc. market value which is $8M. Current Last Sale of JUNO is $19.11 below from SGEN current last sale which is $62.07.
Juno Therapeutics, Inc. declared that it has defeated an try to invalidate a patent exclusively licensed by Juno that covers, among different matters, a chimeric antigen receptor (automobile) T cellular used for the treatment of B-cellular malignancies, and that it’s miles suing Kite Pharma, Inc., looking for a declaratory judgment that Kite’s lead product candidate, KTE-C19, will infringe the patent whilst commercially produced.
In August 2015, Kite Pharma, Inc. filed an inter partes evaluation in the U.S. Patent & Trademark office in a try to invalidate U.S. Patent No. 7,446,190 through tough all of its claims. Juno completely licenses the ’a hundred ninety patent, titled “Nucleic Acids Encoding Chimeric T cellular Receptors,” from Sloan Kettering Institute for most cancers studies, an associate of Memorial Sloan Kettering cancer middle. The patent covers, amongst other things, a assemble for a CD-19 focused vehicle T mobile treatment that employs a CD28 costimulatory area.
The U.S. Patent & Trademark office instituted a evaluation of the patent and on December 16, 2016 issued a final written decision upholding all of the claims of the patent.